Status: Therapeutic Antibody Discovery

CGEN-15049 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.

CGEN-15049 was shown to inhibit the activity of immune cells that play important roles in immune responses against cancer, such as natural killer cells (NKs) and tumor antigen-specific cytotoxic T lymphocytes (CTLs), including tumor infiltrating lymphocytes (TILs) from melanoma patients. Furthermore, CGEN-15049 was shown to promote differentiation of inducible regulatory T cells (iTregs), a major cellular component of the immunosuppressive tumor microenvironment. Initial results have shown that CGEN-15049 is expressed in various cancers and within the tumor infiltrating immune cells.